Fluticasone mdi (DrugBank: Fluticasone)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
98 | 好酸球性消化管疾患 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02019758 (ClinicalTrials.gov) | January 1, 2015 | 18/12/2013 | Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis | Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Oral Viscous Budesonide;Drug: Fluticasone MDI;Drug: Placebo slurry;Drug: Placebo inhaler | University of North Carolina, Chapel Hill | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 16 Years | 80 Years | All | 129 | Phase 4 | United States |